EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 338 filers reported holding EXELIXIS INC in Q1 2020. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $3,908,430 | -19.2% | 173,246 | -14.4% | 0.01% | -16.7% |
Q1 2024 | $4,834,779 | +16.4% | 202,292 | +17.3% | 0.01% | +20.0% |
Q4 2023 | $4,152,268 | +4.6% | 172,508 | -3.3% | 0.01% | -16.7% |
Q3 2023 | $3,970,648 | +13.9% | 178,416 | -2.7% | 0.01% | +20.0% |
Q2 2023 | $3,485,084 | -28.6% | 183,329 | -28.8% | 0.01% | -28.6% |
Q1 2023 | $4,881,398 | +19.4% | 257,322 | -1.3% | 0.01% | +16.7% |
Q4 2022 | $4,086,990 | -5.7% | 260,733 | -4.0% | 0.01% | -14.3% |
Q3 2022 | $4,336,000 | -23.4% | 271,709 | -1.1% | 0.01% | -12.5% |
Q2 2022 | $5,660,000 | -17.1% | 274,645 | -9.5% | 0.01% | -11.1% |
Q1 2022 | $6,831,000 | +22.2% | 303,581 | +1.1% | 0.01% | +28.6% |
Q4 2021 | $5,590,000 | -12.6% | 300,393 | -1.3% | 0.01% | -12.5% |
Q3 2021 | $6,398,000 | +16.8% | 304,221 | +1.2% | 0.01% | +14.3% |
Q2 2021 | $5,478,000 | -11.8% | 300,665 | +9.2% | 0.01% | -22.2% |
Q1 2021 | $6,208,000 | +5.2% | 275,443 | -6.3% | 0.01% | 0.0% |
Q4 2020 | $5,900,000 | -12.9% | 293,973 | +7.1% | 0.01% | -30.8% |
Q3 2020 | $6,773,000 | -46.3% | 274,534 | -49.7% | 0.01% | 0.0% |
Q2 2020 | $12,612,000 | +158.9% | 546,196 | +99.2% | 0.01% | +8.3% |
Q1 2020 | $4,872,000 | +4.2% | 274,177 | +4.7% | 0.01% | +33.3% |
Q4 2019 | $4,674,000 | +0.9% | 261,975 | +2.1% | 0.01% | -10.0% |
Q3 2019 | $4,631,000 | -15.4% | 256,546 | +0.2% | 0.01% | -16.7% |
Q2 2019 | $5,474,000 | -10.8% | 256,130 | -0.6% | 0.01% | -7.7% |
Q1 2019 | $6,135,000 | -60.7% | 257,762 | -67.5% | 0.01% | 0.0% |
Q4 2018 | $15,603,000 | +97.9% | 793,305 | +78.3% | 0.01% | +62.5% |
Q3 2018 | $7,884,000 | +138.0% | 444,960 | +189.0% | 0.01% | 0.0% |
Q2 2018 | $3,313,000 | +39.9% | 153,943 | +44.0% | 0.01% | +33.3% |
Q1 2018 | $2,368,000 | -12.3% | 106,902 | +20.4% | 0.01% | 0.0% |
Q4 2017 | $2,700,000 | +41.5% | 88,816 | +12.8% | 0.01% | +20.0% |
Q3 2017 | $1,908,000 | -5.3% | 78,725 | -3.7% | 0.01% | 0.0% |
Q2 2017 | $2,014,000 | – | 81,755 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |